MegaPro Biomedical Co., Ltd.(TW:6827)
NT$15.30+0.25 (+1.66%)
TW:6827
MegaPro Biomedical Co., Ltd. financials statements
NT$15.30
At close:+0.25 (+1.66%)
MegaPro Biomedical Co., Ltd. (6827) Ratios
MegaPro Biomedical Co., Ltd. Ratios
TW:6827's free cash flow for Q2 2026 was NT$-34.91M. For the 2026 fiscal year, TW:6827's free cash flow was decreased by NT$-717.00K and operating cash flow was NT$-34.20M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 16.17 | 10.41 | 10.77 | 17.77 | 31.71 |
| Quick Ratio | 16.17 | 10.41 | 10.77 | 17.77 | 31.71 |
| Cash Ratio | 7.05 | 5.23 | 9.61 | 9.18 | 14.38 |
| Solvency Ratio | -6.39 | -7.35 | -4.35 | -3.46 | -3.05 |
| Operating Cash Flow Ratio | -7.27 | -8.59 | -5.10 | -5.27 | -7.29 |
| Short-Term Operating Cash Flow Coverage | -5518.57 | -5544.85 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 241.43M | NT$ 154.60M | NT$ 185.16M | NT$ 250.70M | NT$ 342.95M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.03 | 0.03 | 0.03 | 0.03 |
| Debt-to-Equity Ratio | 0.01 | 0.03 | 0.03 | 0.03 | 0.03 |
| Debt-to-Capital Ratio | 0.01 | 0.03 | 0.03 | 0.03 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.06 | 1.10 | 1.09 | 1.09 | 1.07 |
| Debt Service Coverage Ratio | -653.52 | -306.89 | -374.01 | -263.60 | 0.00 |
| Interest Coverage Ratio | -866.57 | -399.54 | -476.23 | -328.16 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.04 | 0.10 | 0.17 | 0.20 | 0.25 |
| Net Debt to EBITDA | 1.05 | 0.56 | 1.63 | 1.37 | 1.89 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | -122807.14% | -92227.78% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | -1168500.00% | -706983.33% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | -1045607.14% | -612988.89% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | -1287092.86% | -780483.33% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | -1171721.43% | -708622.22% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | -1171721.43% | -708600.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | -1171735.71% | -708600.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.39% | 100.00% |
| EBT Per EBIT | 99.60% | 91.04% | 90.79% | 91.41% | 88.29% |
| Return on Assets (ROA) | -42.70% | -73.13% | -43.30% | -32.60% | -20.61% |
| Return on Equity (ROE) | -45.35% | -80.27% | -47.40% | -35.54% | -21.97% |
| Return on Capital Employed (ROCE) | -45.47% | -86.82% | -51.08% | -37.23% | -23.99% |
| Return on Invested Capital (ROIC) | -44.98% | -85.67% | -50.59% | -36.94% | -23.84% |
| Return on Tangible Assets | -43.63% | -76.30% | -45.51% | -34.59% | -21.88% |
| Earnings Yield | -14.21% | -18.42% | -10.25% | -10.72% | -5.53% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 38898.57 | 45706.11 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 38898.57 | 45706.11 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 38898.57 | 45706.11 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.72 | -2.36 | -1.92 | -1.49 | -1.57 |
| Free Cash Flow Per Share | -1.74 | -2.37 | -2.01 | -1.74 | -1.90 |
| Dividend Paid and CapEx Coverage Ratio | -129.78 | -123.11 | -22.73 | -6.13 | -4.75 |
| Capital Expenditure Coverage Ratio | -129.78 | -123.11 | -22.73 | -6.13 | -4.75 |
| Operating Cash Flow Coverage Ratio | -40.28 | -25.50 | -11.99 | -7.58 | -6.32 |
| Operating Cash Flow to Sales Ratio | 0.00 | -10297.57 | -5538.83 | 0.00 | 0.00 |
| Free Cash Flow Yield | -13.94% | -16.32% | -8.36% | -9.24% | -6.39% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -7.03 | -5.43 | -9.76 | -9.31 | -18.05 |
| Price-to-Sales (P/S) Ratio | 0.00 | 63613.98 | 69150.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.19 | 4.36 | 4.63 | 3.31 | 3.97 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.18 | -6.13 | -11.96 | -10.82 | -15.65 |
| Price-to-Operating Cash Flow Ratio | -7.23 | -6.18 | -12.48 | -12.58 | -18.94 |
| Price-to-Earnings Growth (PEG) Ratio | 0.21 | -0.61 | -0.45 | -0.42 | 0.42 |
| Enterprise Value Multiple | -7.01 | -5.52 | -9.65 | -9.33 | -17.85 |
| Enterprise Value | 728.55M | 808.57M | 1.07B | 908.70M | 1.46B |
| EV to EBITDA | -7.01 | -5.52 | -9.65 | -9.33 | -17.85 |
| EV to Sales | 0.00 | 57755.27 | 59174.45 | 0.00 | 0.00 |
| EV to Free Cash Flow | -6.24 | -5.56 | -10.23 | -9.44 | -14.15 |
| EV to Operating Cash Flow | -6.29 | -5.61 | -10.68 | -10.97 | -17.13 |
| Tangible Book Value Per Share | 3.81 | 3.19 | 4.91 | 5.32 | 7.04 |
| Shareholders’ Equity Per Share | 3.90 | 3.34 | 5.19 | 5.67 | 7.51 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.00 | 0.00 | -0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.77 | -2.68 | -2.46 | -2.02 | -1.65 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 11208.00 | 6441.94 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 1663.93 | 1363.89 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 1133.79 | 873.33 | 0.00 | 0.00 |
| Income Quality | 0.97 | 0.88 | 0.78 | 0.74 | 0.95 |
Currency in TWD
